Literature DB >> 22585712

Differential expression of RON in small and non-small cell lung cancers.

Rajani Kanteti1, Soundararajan Krishnaswamy, Daniel Catenacci, Yi-Hung Carol Tan, Essam EL-Hashani, Gustavo Cervantes, Aliya N Husain, Maria Tretiakova, Everett E Vokes, Heather Huet, Ravi Salgia.   

Abstract

RON is a MET related receptor tyrosine kinase (RTK) and its natural ligand is macrophage stimulating protein (MSP). RON plays a very important role in the regulation of inflammation. Several studies have previously reported overexpression of RON in a variety of cancers including lung and identified numerous RON alternate splice forms that very likely contribute to tumor growth and metastasis. Here, we have analyzed the expression of total RON protein as well as its kinase-active form (phospho-RON) in 175 archival lung tumor FFPE (formalin fixed paraffin embedded) samples that included non-small-cell lung cancer (NSCLC) and small cell lung cancer (SCLC), and their metastatic forms. The frequency and intensity of RON protein expression was much higher in lung tumors of neuroendocrine origin such as SCLC and in secondary tumors that metastasized to brain. In addition, the majority of the expressed RON protein was phospho-RON. We also identified 62, and 30 kDa isoforms of RON (GenBank accession numbers are JN689381 and JN689382) using RNA isolated from pooled lung cancer cell lines and RT-PCR. A majority of the NSCLC cell lines expressed a 150 kDa band that corresponded to the RON β chain and 120 kDa band in the panel of SCLC cell lines tested. RON was expressed on the cell surface in NSCLC cell lines. Finally, knock down of RON expression resulted in a significant loss in viability as well as motility in lung cancer cells suggesting that RON is a potential therapeutic target.
Copyright © 2012 Wiley Periodicals, Inc.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22585712     DOI: 10.1002/gcc.21968

Source DB:  PubMed          Journal:  Genes Chromosomes Cancer        ISSN: 1045-2257            Impact factor:   5.006


  20 in total

Review 1.  MSP-RON signalling in cancer: pathogenesis and therapeutic potential.

Authors:  Hang-Ping Yao; Yong-Qing Zhou; Ruiwen Zhang; Ming-Hai Wang
Journal:  Nat Rev Cancer       Date:  2013-07       Impact factor: 60.716

2.  Macrophage stimulating protein promotes liver metastases of small cell lung cancer cells by affecting the organ microenvironment.

Authors:  Seidai Sato; Masaki Hanibuchi; Takuya Kuramoto; Nodoka Yamamori; Hisatsugu Goto; Hirohisa Ogawa; Atsushi Mitsuhashi; Trung The Van; Soji Kakiuchi; Shin-ichi Akiyama; Yasuhiko Nishioka; Saburo Sone
Journal:  Clin Exp Metastasis       Date:  2012-09-26       Impact factor: 5.150

3.  Recepteur d'Origine nantais (RON) tyrosine kinase splicing variants lacking exons 18 and 19 occur ubiquitously in lung cancer.

Authors:  Soundararajan Krishnaswamy; Abdul Khader Mohammed; Osama E Amer; Gyanendra Tripathi; Majed S Alokail; Nasser M Al-Daghri
Journal:  Int J Clin Exp Med       Date:  2015-11-15

4.  Dramatic antitumor effects of the dual MET/RON small-molecule inhibitor LY2801653 in non-small cell lung cancer.

Authors:  Ichiro Kawada; Rifat Hasina; Qudsia Arif; Jeffrey Mueller; Erin Smithberger; Aliya N Husain; Everett E Vokes; Ravi Salgia
Journal:  Cancer Res       Date:  2013-12-04       Impact factor: 12.701

5.  Cell surface marker profiling of human tracheal basal cells reveals distinct subpopulations, identifies MST1/MSP as a mitogenic signal, and identifies new biomarkers for lung squamous cell carcinomas.

Authors:  Emily Van de Laar; Monica Clifford; Stefan Hasenoeder; Bo Ram Kim; Dennis Wang; Sharon Lee; Josh Paterson; Nancy M Vu; Thomas K Waddell; Shaf Keshavjee; Ming-Sound Tsao; Laurie Ailles; Nadeem Moghal
Journal:  Respir Res       Date:  2014-12-31

6.  Biological evaluation of antibody-maytansinoid conjugates as a strategy of RON targeted drug delivery for treatment of non-small cell lung cancer.

Authors:  Liang Feng; Hang-Ping Yao; Yong-Qing Zhou; Jianwei Zhou; Ruiwen Zhang; Ming-Hai Wang
Journal:  J Exp Clin Cancer Res       Date:  2016-04-22

7.  RON tyrosine kinase mutations in brain metastases from lung cancer.

Authors:  Melissa Milan; Silvia Benvenuti; Alice Maria Balderacchi; Anna Rita Virzì; Alessandra Gentile; Rebecca Senetta; Paola Cassoni; Paolo Maria Comoglio; Giulia Maria Stella
Journal:  ERJ Open Res       Date:  2018-03-06

8.  Targeted agents in non-small cell lung cancer therapy: What is there on the horizon?

Authors:  Victoria M Villaflor; Ravi Salgia
Journal:  J Carcinog       Date:  2013-03-18

Review 9.  Managing Patients With Relapsed Small-Cell Lung Cancer.

Authors:  Jun Gong; Ravi Salgia
Journal:  J Oncol Pract       Date:  2018-06       Impact factor: 3.714

Review 10.  Pathogenesis of RON receptor tyrosine kinase in cancer cells: activation mechanism, functional crosstalk, and signaling addiction.

Authors:  Ming-Hai Wang; Ruiwen Zhang; Yong-Qing Zhou; Hang-Ping Yao
Journal:  J Biomed Res       Date:  2013-07-30
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.